Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 671

Sort by

Sort Order Select

Journal Articles

Effects of Targeting the Interleukin-1 Receptor in a Murine Model of Sickle Cell Disease

Jessica Venugopal, PhD, Jintao Wang, PhD, Chiao Guo, Daniel Eitzman, MD

Blood (2019) 134 (Supplement_1): 2259.

https://doi.org/10.1182/blood-2019-128980

Published: 2019

Journal Articles

Iron Restriction Improves Markers of Disease Severity in the Townes Mouse Model of Sickle Cell Anemia

Nermi Parrow, PhD, Pierre-Christian Violet, PhD, Nisha George, PhD, Faris Ali, Shivam Bhanvadia, Mark Levine, MD, Robert E Fleming, MD

Blood (2019) 134 (Supplement_1): 2261.

https://doi.org/10.1182/blood-2019-130732

Published: 2019

Journal Articles

Clinical and Cytogenomic Features of Lymphoblastic Leukemia with Intrachromosomal Amplification of Chromosome 21 (iAMP21) in the Context of Constitutional Ring Chromosome 21

Tatiana Tvrdik, PhD MSc, Kristian T. Schafernak, MD MPH, Jeffrey R Jacobsen, MD, Reha Toydemir, MD PhD, Alexandra M Walsh, MD, Bo Hong, MD

Blood (2019) 134 (Supplement_1): 5208.

https://doi.org/10.1182/blood-2019-123766

Published: 2019

Journal Articles

A Clinically-Indolent Variant of Extranodal NK/T Cell Lymphoma with Unique Immunophenotypic Profile and Superior Outcome

Fabiola Valvert, MD, Elizabeth Solorzano, MSc, Edward Briercheck, MD, Marcos Mauricio Siliézar Tala, MD, Yasodha Natkunam, MD PhD, David M. Weinstock, MD, Oscar Silva, MD PhD

Blood (2019) 134 (Supplement_1): 5278.

https://doi.org/10.1182/blood-2019-131620

Published: 2019

Journal Articles

Prognosis in Patients with Human Immunodeficiency Virus Infection and Advanced Clinical Stage Classic Hodgkin's Lymphoma

Juan J delMoral-Diez, MD, Elena Juventina Tuna-Aguilar, MD, Alvaro Aguayo, MD, Antonio Olivas-Martinez, MD, Gladys P Agreda-Vasquez, MD

Blood (2019) 134 (Supplement_1): 5281.

https://doi.org/10.1182/blood-2019-123792

Published: 2019

Journal Articles

Administration of Plerixafor in Poor Mobilizers Allows Mobilization of Haematopoietic Progenitors: Clonogenic Potential and Engraftment Analysis

Laura Pezzetti, MSc, Giambattista Bertani, MD, Liliana Intropido, MSc, Tiziana Lamacchia, MSc, Mariateresa Pugliano, MD, Elisabetta Bice Volpato, MD, Elisa Zucchetti, MD, Giovanni Grillo, MD, Roberto Cairoli, MD

Blood (2019) 134 (Supplement_1): 5633.

https://doi.org/10.1182/blood-2019-125055

Published: 2019

Journal Articles

Eltrombopag Following Chemotherapy and G-CSF+/- Plerixafor for Mobilization and Collection of Hematopoietic Progenitor Cells (HPC) in Lymphoma and Myeloma Patients

Krishna Joshi, MD, Appalanaidu Sasapu, MD, Muthu Veeraputhiran, MD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Michele H Cottler-Fox, MD

Blood (2019) 134 (Supplement_1): 5638.

https://doi.org/10.1182/blood-2019-124629

Published: 2019

Journal Articles

Comparison of Early Versus Delayed Filgrastim (G-CSF) Administration Following Autologous Stem Cell Transplantation in Patients with Multiple Myeloma - Real-World Data from a Single-Center Institution

Blood (2019) 134 (Supplement_1): 5644.

https://doi.org/10.1182/blood-2019-130914

Published: 2019

Journal Articles

Validation of Low Risk Prognostic Scoring System (LR-PSS) in Patients with Lower Risk IPSS-R Myelodysplastic Syndrome. Results from a Single Center

Montserrat Arnan Sangerman, MD PhD, Helena Pomares, MD PhD, Esther Alonso, MD, Mercedes Galiano, Maite Encuentra, Javier Grau, MD PhD, Anna Sureda, MD PhD

Blood (2019) 134 (Supplement_1): 4270.

https://doi.org/10.1182/blood-2019-127901

Published: 2019

Journal Articles

Strategies for Analysis of Novel Molecular Variants in the RUNX1 Gene As a Cause of Familial Platelet Disorder with Predisposition to Acute Myeloid Leukemia (FPD/AML)

Veronica Palma-Barqueros, MSc, Jf Ruiz-Pividal, MSc, Jose Maria Bastida, MD PhD, Natalia Bohdan, MJ Lopez-Andreu, PhD, Raul Teruel-Montoya, PhD, Ana Isabel Antón, PhD, Francisca Ferrer Marin, MD PhD, Jose Padilla, Rosa Cifuentes-Riquelme, A Marín-Quilez, MSc, Marta Martín Izquierdo, MSc, Rocio Benito, PhD, Vicente Vicente, MD PhD, Jesus Maria . Hernández-Rivas, MD, José Ramón González-Porras, MD PhD, Jose Rivera, PhD, Maria Luisa Lozano, MD PhD

Blood (2019) 134 (Supplement_1): 2359.

https://doi.org/10.1182/blood-2019-128736

Published: 2019

Journal Articles

Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC) ASTRAL-1 Study: Analysis By Number of Cycles

Blood (2019) 134 (Supplement_1): 2591.

https://doi.org/10.1182/blood-2019-127253

Published: 2019

Journal Articles

First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl

Jae H. Park, MD, Madhulika Shukla, Jose M Salcedo, Shreya Vemuri, Julie C Kinoshita, Marissa D Smith, Eric S. Winer, MD, Omar Abdel-Wahab, MD, Martin S. Tallman, MD

Blood (2019) 134 (Supplement_1): 3998.

https://doi.org/10.1182/blood-2019-124478

Published: 2019

Journal Articles

Phase II Study of Eltrombopag in Subjects with Fanconi Anemia

Daisuke Araki, MD, Ma Evette Barranta, Fariba Chinian, MS, Julie Erb-Alvarez, MPH, Thomas Winkler, MD, Neelam Giri, MD, Andre Larochelle, MD PhD

Blood (2019) 134 (Supplement_1): 3753.

https://doi.org/10.1182/blood-2019-123151

Published: 2019

Journal Articles

Pilot Study of Telmisartan (Micardis) for Prevention of Acute Graft Vs. Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation: Interim Analysis

Sujatha Iyengar, PhD, Scott D. Rowley, MD, Caixin Zhan, Michele L. Donato, MD, Themba Nyirenda, PhD, David H. Schwartz, MD PhD

Blood (2019) 134 (Supplement_1): 4546.

https://doi.org/10.1182/blood-2019-129378

Published: 2019

Journal Articles

Clinical and Genomic Factors Are Predictive of Response and Prognostic of Progression-Free Survival in Patients with Waldenström Macroglobulinemia Treated with Ibrutinib

Jorge J. Castillo, MD, Joshua Gustine, MPH, Maria Demos, Andrew Keezer, BS, Kirsten Meid, MPH, Gloria G Chan, MS, Jiaji G Chen, Maria Luisa Guerrera, MD, Amanda Kofides, Manit Munshi, MS, Nicholas Tsakmaklis, Xia Liu, MD, Lian Xu, MS, Guang Yang, PhD, Zachary R Hunter, PhD, Steven P Treon, MD PhD FRCP

Blood (2019) 134 (Supplement_1): 2823.

https://doi.org/10.1182/blood-2019-125069

Published: 2019

Journal Articles

CXCR4 Mutational Status Does Not Impact Outcomes in Patients with Waldenstrom Macroglobulinemia Treated with Proteasome Inhibitors

Jorge J. Castillo, MD, Joshua Gustine, MPH, Maria Demos, Andrew Keezer, BS, Kirsten Meid, MPH, Toni Dubeau, NP, Gloria G Chan, MS, Jiaji Chen, BS, Maria Luisa Guerrera, MD, Amanda Kofides, Manit Munshi, MS, Nicholas Tsakmaklis, Xia Liu, MD, Lian Xu, MS, Guang Yang, PhD, Zachary R Hunter, PhD, Steven P Treon, MD PhD FRCP

Blood (2019) 134 (Supplement_1): 2830.

https://doi.org/10.1182/blood-2019-122349

Published: 2019

Journal Articles

Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis

Blood (2019) 134 (Supplement_1): 558.

https://doi.org/10.1182/blood-2019-131217

Published: 2019

Journal Articles

JAK2 V617F Clonal Hematopoiesis Stratifies By Peripheral Blood Counts.

Andrew Sochacki, MD, Shilin Zhao, PhD, Cosmin Adrian Bejan, PhD, Travis Spaulding, MD, Shannon Stockton, MD, Alexander Silver, Dixon Dorand, MD PhD, Siwei Zhang, PhD, Thomas Stricker, MD PhD, Yaomin Xu, PhD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 1203.

https://doi.org/10.1182/blood-2019-129639

Published: 2019

Journal Articles

Increased Platelet Force Is Associated with Decreased Bleeding Severity in Pediatric Immune Thrombocytopenia

Oluwamayokun T. Oshinowo, BS, Renee Copeland, BS, Christina Caruso, MD, Meredith E. Fay, BS, Traci Leong, PhD, Carolyn M. Bennett, MDMSc, Wilbur A. Lam, MD PhD, David R. Myers, PhD

Blood (2019) 134 (Supplement_1): 1096.

https://doi.org/10.1182/blood-2019-129573

Published: 2019

Journal Articles

Common Myeloid Progenitors As Biomarkers of Hbf Response to Hydroxyurea in Sickle Cell Disease

Caterina P. Minniti, MD, Seda S. Tolu, MD, Kai Wang, PhD, Zi Yan, Andrew Crouch, Gracy Sebastian, NP, Mark Chaitowitz, MD, Evan Schwechter, MD, Joan Uehlinger, MD, Deepa Manwani, MD, Eric Fornari, MD, Eric E. Bouhassira, PhD

Blood (2019) 134 (Supplement_1): 4827.

https://doi.org/10.1182/blood-2019-131466

Published: 2019

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Effects of Targeting the Interleukin-1 Receptor in a Murine Model of Sickle Cell Disease

Iron Restriction Improves Markers of Disease Severity in the Townes Mouse Model of Sickle Cell Anemia

Clinical and Cytogenomic Features of Lymphoblastic Leukemia with Intrachromosomal Amplification of Chromosome 21 (iAMP21) in the Context of Constitutional Ring Chromosome 21

A Clinically-Indolent Variant of Extranodal NK/T Cell Lymphoma with Unique Immunophenotypic Profile and Superior Outcome

Prognosis in Patients with Human Immunodeficiency Virus Infection and Advanced Clinical Stage Classic Hodgkin's Lymphoma

Administration of Plerixafor in Poor Mobilizers Allows Mobilization of Haematopoietic Progenitors: Clonogenic Potential and Engraftment Analysis

Eltrombopag Following Chemotherapy and G-CSF+/- Plerixafor for Mobilization and Collection of Hematopoietic Progenitor Cells (HPC) in Lymphoma and Myeloma Patients

Comparison of Early Versus Delayed Filgrastim (G-CSF) Administration Following Autologous Stem Cell Transplantation in Patients with Multiple Myeloma - Real-World Data from a Single-Center Institution

Validation of Low Risk Prognostic Scoring System (LR-PSS) in Patients with Lower Risk IPSS-R Myelodysplastic Syndrome. Results from a Single Center

Strategies for Analysis of Novel Molecular Variants in the RUNX1 Gene As a Cause of Familial Platelet Disorder with Predisposition to Acute Myeloid Leukemia (FPD/AML)

Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC) ASTRAL-1 Study: Analysis By Number of Cycles

First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl

Phase II Study of Eltrombopag in Subjects with Fanconi Anemia

Pilot Study of Telmisartan (Micardis) for Prevention of Acute Graft Vs. Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation: Interim Analysis

Clinical and Genomic Factors Are Predictive of Response and Prognostic of Progression-Free Survival in Patients with Waldenström Macroglobulinemia Treated with Ibrutinib

CXCR4 Mutational Status Does Not Impact Outcomes in Patients with Waldenstrom Macroglobulinemia Treated with Proteasome Inhibitors

Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis

JAK2 V617F Clonal Hematopoiesis Stratifies By Peripheral Blood Counts.

Increased Platelet Force Is Associated with Decreased Bleeding Severity in Pediatric Immune Thrombocytopenia

Common Myeloid Progenitors As Biomarkers of Hbf Response to Hydroxyurea in Sickle Cell Disease

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only